Rovalpituzumab Tesirine (Rova-T) A DLL3 Target in SCLC

Rovalpituzumab Tesirine (Rova-T) A DLL3 Target in SCLC


2 years
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0

Charles Rudin, MD, PhD of Memorial Sloan Kettering Cancer Center discusses Rovalpituzumab Tesirine (Rova-T) a DLL3 target in SCLC. According to Dr. Rudin, Rova-T is an antibody drug conjugate that is directed to a cell surface target on small-cell lung cancer called DLL3. The drug directs attacks into the small-cell lung cancer cells, internalizes those molecules and releases the toxin inside the cell.Initial Phase I of the study has already been completed which focus on small-cell lung cancer patients. Results show that 1/3 of patients are having an objective response to the drug. This will be a new biomarker and the target of this antibody drug conjugate is the DLL3 itself. Based on numbers, it is observed that patients with tumors cells of high DLL3 tend to respond very well compared to patients whose tumor cells didnt show high level of activity or high level of expression.





SCLC, small-cell lung cancer cells, Rovalpituzumab Tesirine (Rova-T), DLL3 target in SCLC,antibody drug, DLL3, Phase I, small-cell lung cancer patients

Up Next Autoplay